Burden of Influenza‐Like Illness and Effectiveness of Influenza Vaccination among Working Adults Aged 50–64 Years

Nichol, Kristin L.; D'Heilly, Sarah J; Greenberg, Michael; Ehlinger, Edward

doi:10.1086/595842

Cited by 103 publications

(93 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18,19 Another study in the US found that in working adults 50 to 64 y of age, vaccination reduces days with decreased ability to perform activities, work days lost and days working while ill with influenza-like illness by more than 60%. 20 In addition, the PRISMA study found that influenza vaccination prevented 78% of deaths, 87% of hospitalizations and 26% of general practitioner visits in high-risk adults between the ages of 18 and 64 y. 21 Cost-effectiveness modeling indicates that in adults under 50 y of age, vaccination is the most cost-effective means of preventing influenza and is more…”

Section: Influenza Vaccination Efficacy In Adults 18 To 59 Years Of Agementioning

confidence: 99%

Intanza^®9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age

Leroux-Roels

Weber

2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Influenza Vaccination Efficacy In Adults 18 To 59 Years Of Agementioning

confidence: 99%

Intanza^®9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age

Leroux-Roels

Weber

2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Seasonal influenza is an important cause of morbidity and mortality 1 . Influenza viruses have the potential to cause not only epidemics but also occasional pandemics.…”

Section: Introductionmentioning

confidence: 99%

The post‐infection outcomes of influenza and acute respiratory infection in patients above 50 years of age in Japan: an observational study

Ikematsu¹,

Takeuchi²,

Rosenlund³

et al. 2011

Influenza Resp Viruses

View full text Add to dashboard Cite

Please cite this paper as: Ikematsu et al. (2011) The post‐infection outcomes of influenza and acute respiratory infection in patients above 50 years of age in Japan: an observational study. Influenza and Other Respiratory Viruses 6(3), 211–217. Objectives Influenza can be a serious illness, especially for older people, and reducing the impact of influenza in elderly is important. The objective of this study was to estimate the prevalence and postinfection outcomes of influenza among the over‐50 population in Japan. Design An observational study was designed to ascertain the proportion of influenza cases in a population aged ≥50 years with acute respiratory infection (ARI) and to determine the postinfection outcomes of their illness during the 2008–09 influenza season in Japan. Respiratory specimens obtained from a total of 401 patients were tested by PCR for influenza viruses, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). The effectiveness of the seasonal trivalent influenza vaccine was estimated by a test‐negative case control analysis. Setting Seventeen outpatient clinics located in four separate areas of Japan. Sample Respiratory swab specimens from the ARI patients aged ≥50 years. Main outcome measures Laboratory confirmed influenza in patients presenting with ARI. Results In all, 89 (22.2%) of the patients were positive for one of the tested viruses; 70 (78.7%) with influenza, 17 (19.1%) with RSV, and 2 (2.2%) with hMPV. Cough (95.7% vs 73.4%), loss of appetite (67.1% vs 35.5%), absence from work (50.0% vs 23.0%), impact on daily activity (90.0% vs 62.5%), and caregiver absence from work (5.7% vs 0.6%) were observed higher in influenza patients. The duration of feeling weakness (6.3 ± 5.4 vs 3.6 ± 1.9 days) and average days of reduced activity (5.2 vs 3.6 days) were longer for influenza patients. Vaccine effectiveness was estimated to be 32.1% (95% CI: −14.9, 59.9%). Conclusions Influenza was the dominant ARI‐causing virus and the clinical and socio‐economic outcomes imposed on patients over 50 years of age was high for influenza.

show abstract

“…3,4 Inactivated influenza vaccines, which have been in use for more than 50 years, are safe and effective in preventing laboratory confirmed illness in 70-90% of healthy adults. [5][6][7] Traditionally however, healthy adults in the age group 18-60/65 have been excluded from the targeted priority groups for seasonal influenza vaccination, and vaccination coverage in this age-range remains low. [8][9][10][11] A series of population-based studies of influenza vaccination coverage in five European countries has shown that, while there has been a slight increase in coverage rates in recent years, vaccine uptake remains around 10% among adults in their 20s and 30s, 15% among those in their 40s…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years: Randomized, controlled, Phase III trial

Arnou¹,

Eavis²,

Pardo³

et al. 2010

Human Vaccines

View full text Add to dashboard Cite

Burden of Influenza‐Like Illness and Effectiveness of Influenza Vaccination among Working Adults Aged 50–64 Years

Cited by 103 publications

References 33 publications

Intanza^®9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age

Intanza^®9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age

The post‐infection outcomes of influenza and acute respiratory infection in patients above 50 years of age in Japan: an observational study

Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years: Randomized, controlled, Phase III trial

Contact Info

Product

Resources

About

Burden of Influenza‐Like Illness and Effectiveness of Influenza Vaccination among Working Adults Aged 50–64 Years

Cited by 103 publications

References 33 publications

Intanza®9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age

Intanza®9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age

The post‐infection outcomes of influenza and acute respiratory infection in patients above 50 years of age in Japan: an observational study

Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years: Randomized, controlled, Phase III trial

Contact Info

Product

Resources

About

Intanza^®9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age

Intanza^®9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age